PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase

被引:289
作者
Chan, Rebecca J.
Feng, Gen-Sheng
机构
[1] Burke Med Res Inst, Program Signal Transduct, La Jolla, CA 92037 USA
[2] Burke Med Res Inst, Program Stem Cells & Regenerat, La Jolla, CA 92037 USA
[3] Indiana Univ, Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46204 USA
[4] Xiamen Univ, Biomed Res Inst, Xiamen, Peoples R China
关键词
D O I
10.1182/blood-2006-07-028829
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Elucidation of the molecular mechanisms underlying carcinogenesis has benefited tremendously from the identification and characterization of oncogenes and tumor suppressor genes. One new advance in this field is the identification of PTPN11 as the first proto-oncogene that encodes a cytoplasmic tyrosine phosphatase with 2 Src-homology 2 (SH2) domains (Shp2). This tyrosine phosphatase was previously shown to play an essential role in normal hematopoiesis. More recently, somatic missense PTPN11 gain-of-function mutations have been detected in leukemias and rarely in solid tumors, and have been found to induce aberrant hyperactivation of the Ras-Erk pathway. This progress represents another milestone in the leukemia/cancer research field and provides a fresh view on the molecular mechanisms underlying cell transformation.
引用
收藏
页码:862 / 867
页数:6
相关论文
共 82 条
[1]   Germline mutations in HRAS proto-oncogene cause Costello syndrome [J].
Aoki, Y ;
Niihori, T ;
Kawame, H ;
Kurosawa, K ;
Filocamo, M ;
Kato, K ;
Suzuki, Y ;
Kure, S ;
Matsubara, Y .
NATURE GENETICS, 2005, 37 (10) :1038-1040
[2]   Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation [J].
Araki, T ;
Mohi, MG ;
Ismat, FA ;
Bronson, RT ;
Williams, IR ;
Kutok, JL ;
Yang, WT ;
Pao, LI ;
Gilliland, DG ;
Epstein, JA ;
Neel, BG .
NATURE MEDICINE, 2004, 10 (08) :849-857
[3]   Juvenile myelomonocytic leukemia [J].
Arico, M ;
Biondi, A ;
Pui, CH .
BLOOD, 1997, 90 (02) :479-488
[4]   Occurrence of myeloproliferative disorder in patients with Noonan syndrome [J].
BaderMeunier, B ;
Tchernia, G ;
Mielot, F ;
Fontaine, JL ;
Thomas, C ;
Lyonnet, S ;
Lavergne, JM ;
Dommergues, JP .
JOURNAL OF PEDIATRICS, 1997, 130 (06) :885-889
[5]   Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia [J].
Bentires-Alj, M ;
Paez, JG ;
David, FS ;
Keilhack, H ;
Halmos, B ;
Naoki, K ;
Maris, JM ;
Richardson, A ;
Bardelli, A ;
Sugarbaker, DJ ;
Richards, WG ;
Du, JY ;
Girard, L ;
Minna, JD ;
Loh, ML ;
Fisher, DE ;
Velculescu, VE ;
Vogelstein, B ;
Meyerson, M ;
Sellers, WR ;
Neel, BG .
CANCER RESEARCH, 2004, 64 (24) :8816-8820
[6]   Nf1 and Gmcsf interact in myeloid leukemogenesis [J].
Birnbaum, RA ;
O'Marcaigh, A ;
Wardak, Z ;
Zhang, YY ;
Dranoff, G ;
Jacks, T ;
Clapp, DW ;
Shannon, KM .
MOLECULAR CELL, 2000, 5 (01) :189-195
[7]   Oncogenic kinase signalling [J].
Blume-Jensen, P ;
Hunter, T .
NATURE, 2001, 411 (6835) :355-365
[8]   Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells [J].
Bollag, G ;
Clapp, DW ;
Shih, S ;
Adler, F ;
Zhang, YY ;
Thompson, P ;
Lange, BJ ;
Freedman, MH ;
McCormick, F ;
Jacks, T ;
Shannon, K .
NATURE GENETICS, 1996, 12 (02) :144-148
[9]  
BOULTON TG, 1994, J BIOL CHEM, V269, P11648
[10]   Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder [J].
Braun, BS ;
Tuveson, DA ;
Kong, N ;
Le, DT ;
Kogan, SC ;
Rozmus, J ;
Le Beau, MM ;
Jacks, TE ;
Shannon, KM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (02) :597-602